BIO-PATH HOLDINGS, INC.
BPTH · OTCMCIK 1133818fmd_0EYWD8ESGRGQK4KFPN2F47Q9KMManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2007 to Mar 31, 2026, 73 periods
| Line item | FY2015 | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | 0 | 0 | 0 | 0 | – | – | – | – | – | – |
| Research and development | 3 | 5 | 5 | 5 | 5 | 7 | 6 | 9 | 12 | 7 |
| Total operating expenses | 5 | 8 | 9 | 9 | 9 | 11 | 10 | 14 | 16 | 12 |
| Operating income | (5) | (8) | (9) | (9) | (9) | (11) | (10) | (14) | (16) | (12) |
| Interest and investment income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other non-operating income (expense) | 0 | 2 | 2 | 0 | 0 | 0 | 0 | 0 | (0) | 2 |
| Income before taxes | (5) | (7) | (7) | (9) | (9) | (11) | (10) | (14) | (16) | (10) |
| Income tax expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net income from continuing operations | (5) | (7) | (7) | (9) | (9) | (11) | (10) | (14) | (16) | (10) |
| Net income | (5) | (7) | (7) | (9) | (9) | (11) | (10) | (14) | (16) | (10) |
| Net income to common shareholders | – | (7) | (8) | (9) | – | – | – | – | – | – |